Eflornithine plus Gleostine improved OS and PFS in recurrent grade 3 IDH-mutated astrocytoma compared to Gleostine alone. The STELLAR study reclassified patients using updated WHO 2021 criteria, ...

Currently patients with glioblastoma have a median survival of approximately 14.6 months and 5-year survival rates below 5%.

Voranigo plus Temodar was safe in glioma with IDH1/2 mutations. Among patents with IDH1- or IDH2-mutant glioma, the treatment ...

Gomekli showed an 87% overall response rate in pediatric low-grade glioma with MAPK pathway activation, with a recommended ...

Keytruda and Padcev improve event-free and overall survival for adults with muscle invasive bladder cancer who cannot receive ...

Early data indicate Voranigo (vorasidenib) is being rapidly adopted in patients with isocitrate dehydrogenase–mutated glioma, ...

A breast cancer survivor finds support and friendship through an online group, easing her journey post-diagnosis. The ...

Baker, a patient and patient advocate based in the United Kingdom, received a diagnosis of essential thrombocythemia (ET) in ...

Recent real-world study findings have identified a potential unmet need for an effective early treatment with minimal ...

The lidERA Breast Cancer study is a phase 3, randomized, open-label trial testing whether the adjuvant therapy giredestrant ...

GISTs are solid tumors, primarily in the stomach, characterized by KIT and EGFR mutations, with Gleevec as a key treatment.

Targeted therapies, guided by molecular testing, offer significant benefits, including fewer side effects and personalization ...